Serum bone alkaline phosphatase in assessing illness severity of infected neonates in the neonatal intensive care unit

International Journal of Biological Sciences

Volumn 8, Issue 1, 2011, Pages 30-38

  Zhang, Yaozong ^a   Xue, Chenguang ^b   Zhu, Tian ^a   Du, Xiaolan ^a   Su, Nan ^a   Qi, Huabing ^a   Yang, Jing ^a   Shi, Yuan ^a   Chen, Lin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b NICU of Children's Hospital of Baoding City   (China)

Author keywords

Bone; Bone alkaline phosphatase; Infection; Neonates; Severity

Indexed keywords

EID: 81255143139     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.8.30     Document Type: Article

References (37)

1. Chiesa C, Pacifico L, Rossi N, Panero A, Matrunola M, Mancuso G. Procalcitonin as a marker of nosocomial infections in the neonatal intensive care unit. Intensive care medicine. 2000; 26 Suppl 2: S175-177.
2. Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: Simplified newborn illness severity and mortality risk scores. The Journal of pediatrics. 2001; 138: 92-100.
3. Hoehn T, Drabik A, Lehmann C, Christaras A, Stannigel H, Mayatepek E. Correlation between severity of disease and reimbursement of costs in neonatal and paediatric intensive care patients. Acta Paediatr. 2008; 97: 1438-1442.
4. Dorling JS, Field DJ. Value and validity of neonatal disease severity scoring systems. Archives of disease in childhood. 2008; 93: F80-82.
5. Kocabas E, Sarikcioglu A, Aksaray N, Seydaoglu G, Seyhun Y, Yaman A. Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis. The Turkish journal of pediatrics. 2007; 49: 7-20.
6. Lopez Sastre JB, Perez Solis D, Roques Serradilla V, Fernandez Colomer B, Coto Cotallo GD, Krauel Vidal X, et al. Procalcitonin is not sufficiently reliable to be the sole marker of neonatal sepsis of nosocomial origin. BMC Pediatr. 2006; 6: 16.
7. Kuster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, et al. Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet. 1998; 352: 1271-1277.
8. van Rossum AM, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. The Lancet infectious diseases. 2004; 4: 620-630.
9. Santuz P, Soffiati M, Dorizzi RM, Benedetti M, Zaglia F, Biban P. Procalcitonin for the diagnosis of early-onset neonatal sepsis: a multilevel probabilistic approach. Clinical biochemistry. 2008; 41: 1150-1155.
10. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev. 2008; 29: 403-440.
11. Adams GB, Martin RP, Alley IR, Chabner KT, Cohen KS, Calvi LM, et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol. 2007; 25: 238-243.
12. Lee SH, Kim TS, Choi Y, Lorenzo J. Osteoimmunology: cytokines and the skeletal system. BMB Rep. 2008; 41: 495-510.
13. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007; 130: 456-469.
14. Ferron M, Wei J, Yoshizawa T, Del Fattore A, Depinho RA, Teti A, et al. Insulin Signaling in Osteoblasts Integrates Bone Remodeling and Energy Metabolism. Cell. 2010; 142: 296-308.
15. Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int. 2000; 11 Suppl 6: S18-29.
16. Uemura H, Yasui T, Kiyokawa M, Kuwahara A, Ikawa H, Matsuzaki T, et al. Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. The Journal of endocrinology. 2002; 174: 353-359.
17. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989; 69: 990-1047.
18. Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem. 2000; 37(Pt 4): 432-446.
19. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther. 2008; 12: 157-170.
20. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006; 124: 407-421.
21. Moyer-Mileur LJ, Brunstetter V, McNaught TP, Gill G, Chan GM. Daily physical activity program increases bone mineralization and growth in preterm very low birth weight infants. Pediatrics. 2000; 106: 1088-1092.
22. Vestergaard P. Bone loss associated with gastrointestinal disease: prevalence and pathogenesis. Eur J Gastroenterol Hepatol. 2003; 15: 851-856.
23. Cakir M, Mungan I, Karahan C, Can G, Okten A. Necrotizing enterocolitis increases the bone resorption in premature infants. Early human development. 2006; 82: 405-409.
24. Dollner H, Vatten L, Austgulen R. Early diagnostic markers for neonatal sepsis: comparing C-reactive protein, interleukin-6, soluble tumour necrosis factor receptors and soluble adhesion molecules. Journal of clinical epidemiology. 2001; 54: 1251-1257.
25. Chiesa C, Pellegrini G, Panero A, Osborn JF, Signore F, Assumma M, et al. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clinical chemistry. 2003; 49: 60-68.
26. Somjen D, Tordjman K, Katzburg S, Knoll E, Sharon O, Limor R, et al. Lipoxygenase metabolites are mediators of PTH-dependent human osteoblast growth. Bone. 2008; 42: 491-497.
27. Kulkarni NH, Wei T, Kumar A, Dow ER, Stewart TR, Shou J, et al. Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor. J Cell Biochem. 2007; 102: 1504-1518.
28. Nagasue K, Inaba M, Okuno S, Kitatani K, Imanishi Y, Ishimura E, et al. Serum N-terminal midfragment vs. intact osteocalcin immunoradiometric assay as markers for bone turnover and bone loss in hemodialysis patients. Biomed Pharmacother. 2003; 57: 98-104.
29. Dorling JS, Field DJ, Manktelow B. Neonatal disease severity scoring systems. Archives of disease in childhood. 2005; 90: F11-16.
30. Pettila V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive care medicine. 2002; 28: 1220-1225.
31. Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004; 363: 203-209.
32. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006; 12: 657-664.
33. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006; 24: 33-63.
34. Ng PC. Diagnostic markers of infection in neonates. Archives of disease in childhood. 2004; 89: F229-235.
35. Tsalik EL, Woods CW. Sepsis redefined: the search for surrogate markers. International journal of antimicrobial agents. 2009; 34 Suppl 4: S16-20.
36. Lapillonne A, Basson E, Monneret G, Bienvenu J, Salle BL. Lack of specificity of procalcitonin for sepsis diagnosis in premature infants. Lancet. 1998; 351: 1211-1212.
37. Monneret G, Labaune JM, Isaac C, Bienvenu F, Putet G, Bienvenu J. Increased serum procalcitonin levels are not specific to sepsis in neonates. Clin Infect Dis. 1998; 27: 1559-1561.